Mechanistically probing lipid-sirna nanoparticle-associated toxicities identifies jak inhibitors effective in mitigating multifaceted toxic responses

Molecular Therapy

Volumn 19, Issue 3, 2011, Pages 567-575

  Tao, Weikang ^a   Mao, Xianzhi ^a   Davide, Joseph P ^a   Ng, Bruce ^a   Cai, Mingmei ^a   Burke, Paul A ^a   Sachs, Alan B ^a   Sepp Lorenzino, Laura ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; DEXAMETHASONE; ETORICOXIB; GAMMA INTERFERON; INTERLEUKIN 6; JANUS KINASE 3; LIPID NANOPARTICLE; NANOPARTICLE; PROTEIN P55; PROTEIN P75; PYRROLIDINE DITHIOCARBAMATE; RAPAMYCIN; SMALL INTERFERING RNA; TACROLIMUS; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE SILENCING; HEMATURIA; IC 50; INNATE IMMUNITY; LETHALITY; MOUSE; NONHUMAN; PROTECTION; RAT; RNA INTERFERENCE; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

MAMMALIA; MUS; RODENTIA;

EID: 79952187464     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.282     Document Type: Article

References (50)

1. Dorsett, Y and Tuschl, T (2004). siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3: 318-329. (Pubitemid 38499759)
2. De Fougerolles, A, Vornlocher, H P, Maraganore, J and Lieberman, J (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453. (Pubitemid 47064567)
3. Sepp-Lorenzino, L and Ruddy, M (2008). Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther 84: 628-632.
4. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
5. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
6. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modifed siRNAs. Nature 432: 173-178. (Pubitemid 39545841)
7. Frank-Kamenetsky, M, Grefhorst, A, Anderson, NN, Racie, TS, Bramlage, B, Akinc, A et al. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 11915-11920.
8. Judge, A and MacLachlan, I (2008). Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19: 111-124. (Pubitemid 351271512)
9. Abrams, MT, Koser, ML, Seitzer, J, Williams, SC, DiPietro, MA, Wang, W et al. (2010). Evaluation of effcacy, biodistribution, and infammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther 18: 171-180.
10. Tousignant, JD, Gates, AL, Ingram, LA, Johnson, CL, Nietupski, JB, Cheng, SH et al. (2000). Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 11: 2493-2513.
11. Rudin, CM, Marshall, JL, Huang, CH, Kindler, HL, Zhang, C, Kumar, D et al. (2004). Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10: 7244-7251. (Pubitemid 39487711)
12. Judge, AD, Sood, V, Shaw, JR, Fang, D, McClintock, K and MacLachlan, I (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462. (Pubitemid 41724921)
13. Kim, JY, Choung, S, Lee, EJ, Kim, YJ and Choi, YC (2007). Immune activation by siRNA/liposome complexes in mice is sequence- independent: lack of a role for Tolllike receptor 3 signaling. Mol Cells 24: 247-254. (Pubitemid 350177185)
14. Schlee, M, Hornung, V and Hartmann, G (2006). siRNA and isRNA: two edges of one sword. Mol Ther 14: 463-470. (Pubitemid 44296098)
15. Love, KT, Mahon, KP, Levins, CG, Whitehead, KA, Querbes, W, Dorkin, JR et al. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869.
16. Akinc, A, Goldberg, M, Qin, J, Dorkin, JR, Gamba-Vitalo, C, Maier, M et al. (2009). Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 17: 872-879.
17. Akira, S and Takeda, K (2004). Toll-like receptor signalling. Nat Rev Immunol 4: 499-511. (Pubitemid 38931765)
18. Staros, EB (2005). Innate immunity: New approaches to understanding its clinical signifcance. Am J Clin Pathol 123: 305-312. (Pubitemid 40194095)
19. Barton, GM (2008). A calculated response: control of infammation by the innate immune system. J Clin Invest 118: 413-420. (Pubitemid 351206528)
20. Tak, PP and Firestein, GS (2001). NF-kappaB: a key role in infammatory diseases. J Clin Invest 107: 7-11. (Pubitemid 32047405)
21. Adams, JL, Badger, AM, Kumar, S and Lee, JC (2001). p38 MAP kinase: molecular target for the inhibition of pro-infammatory cytokines. Prog Med Chem 38: 1-60.
22. Guiducci, C, Ghirelli, C, Marloie-Provost, MA, Matray, T, Coffman, RL, Liu, YJ et al. (2008). PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med 205: 315-322. (Pubitemid 351281597)
23. Imada, K and Leonard, WJ (2000). The Jak-STAT pathway. Mol Immunol 37: 1-11. (Pubitemid 30316189)
24. Karin, M, Yamamoto, Y and Wang, QM (2004). The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3: 17-26. (Pubitemid 38088695)
25. Ghoreschi, K, Laurence, A and O'Shea, JJ (2009). Janus kinases in immune cell signaling. Immunol Rev 228: 273-287.
26. Suntharalingam, G, Perry, MR, Ward, S, Brett, SJ, Castello-Cortes, A, Brunner, MD et al. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028. (Pubitemid 44343545)
27. Raper, SE, Chirmule, N, Lee, FS, Wivel, NA, Bagg, A, Gao, GP et al. (2003). Fatal systemic infammatory response syndrome in a ornithine transcarbamylase defcient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158. (Pubitemid 37272241)
28. Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modifed siRNAs. Nat Biotechnol 23: 1002-1007. (Pubitemid 41114035)
29. Judge, AD, Bola, G, Lee, AC and MacLachlan, I (2006). Design of noninfammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505. (Pubitemid 43257617)
30. Park, JM, Kohn, MJ, Bruinsma, MW, Vech, C, Intine, RV, Fuhrmann, S et al. (2006). The multifunctional RNA-binding protein La is required for mouse development and for the establishment of embryonic stem cells. Mol Cell Biol 26: 1445-1451. (Pubitemid 43202569)
31. Moynagh, PN (2003). Toll-like receptor signalling pathways as key targets for mediating the anti-infammatory and immunosuppressive effects of glucocorticoids. J Endocrinol 179: 139-144. (Pubitemid 37461343)
32. Morand, EF (2007). Effects of glucocorticoids on infammation and arthritis. Curr Opin Rheumatol 19: 302-307.
33. Magari, K, Miyata, S, Ohkubo, Y, Mutoh, S and Goto, T (2003). Calcineurin inhibitors exert rapid reduction of infammatory pain in rat adjuvant-induced arthritis. Br J Pharmacol 139: 927-934. (Pubitemid 36877392)
34. Riendeau, D, Percival, MD, Brideau, C, Charleson, S, Dubé, D, Ethier, D et al. (2001). Etoricoxib (MK-0663): preclinical profle and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296: 558-566. (Pubitemid 32112486)
35. Kudlacz, E, Perry, B, Sawyer, P, Conklyn, M, McCurdy, S, Brissette, W et al. (2004). The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 4: 51-57. (Pubitemid 38155489)
36. Podolin, PL, Callahan, J F, Bolognese, BJ, Li, YH, Carlson, K, Davis, TG et al. (2005). Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fuorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinfammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther 312: 373-381. (Pubitemid 40096491)
37. Badger, AM, Bradbeer, JN, Votta, B, Lee, JC, Adams, JL and Griswold, DE (1996). Pharmacological profle of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279: 1453-1461. (Pubitemid 27166795)
38. Adams, JL, Boehm, JC, Gallagher, TF, Kassis, S, Webb, EF, Hall, R et al. (2001). Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg Med Chem Lett 11: 2867-2870.
39. Yatscoff, RW, Wang, P, Chan, K, Hicks, D and Zimmerman, J (1995). Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 17: 666-671.
40. Changelian, PS, Flanagan, ME, Ball, DJ, Kent, CR, Magnuson, KS, Martin, WH et al. (2003). Prevention of organ allograft rejection by a specifc Janus kinase 3 inhibitor. Science 302: 875-878. (Pubitemid 37339629)
41. Ui, M, Okada, T, Hazeki, K and Hazeki, O (1995). Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem Sci 20: 303-307.
42. Karaman, MW, Herrgard, S, Treiber, DK, Gallant, P, Atteridge, CE, Campbell, BT et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
43. Thomis, DC, Gurniak, CB, Tivol, E, Sharpe, AH and Berg, LJ (1995). Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270: 794-797.
44. Yamaoka, K, Min, B, Zhou, YJ, Paul, WE and O'shea, JJ (2005). Jak3 negatively regulates dendritic-cell cytokine production and survival. Blood 106: 3227-3233. (Pubitemid 41565923)
45. Peschon, JJ, Torrance, DS, Stocking, KL, Glaccum, MB, Otten, C, Willis, CR et al. (1998). TNF receptor-defcient mice reveal divergent roles for p55 and p75 in several models of infammation. J Immunol 160: 943-952. (Pubitemid 28049339)
46. Fattori, E, Cappelletti, M, Costa, P, Sellitto, C, Cantoni, L, Carelli, M et al. (1994). Defective infammatory response in interleukin 6-defcient mice. J Exp Med 180: 1243-1250. (Pubitemid 24289598)
47. Dalton, DK, Pitts-Meek, S, Keshav, S, Figari, IS, Bradley, A and Stewart, TA (1993). Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259: 1739-1742. (Pubitemid 23114658)
48. Joseph, L, Fink, LM and Hauer-Jensen, M (2002). Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood Coagul Fibrinolysis 13: 105-116. (Pubitemid 35001673)
49. Furie, MB and Randolph, GJ (1995). Chemokines and tissue injury. Am J Pathol 146: 1287-1301.
50. Rommel, C, Camps, M and Ji, H (2007). PI3K delta and PI3K gamma: partners in crime in infammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7: 191-201.